Ocular Therapeutix (OCUL) Share-based Compensation (2013 - 2026)

Ocular Therapeutix's Share-based Compensation history runs 14 years deep, the most recent figure standing at $15.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 49.02% year-over-year to $15.6 million; the TTM figure through Mar 2026 stood at $48.3 million (up 35.75% YoY), while the FY2025 annual figure was $43.2 million, up 30.43% from the prior year.
• Share-based Compensation was $15.6 million for Q1 2026 at Ocular Therapeutix, up from $11.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $15.6 million in Q1 2026 to a low of $4.2 million in Q1 2022.
• Historically, Share-based Compensation has averaged $7.5 million across 5 years, with a median of $6.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 155.9% in 2024, then dropped 14.3% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $4.2 million in 2022, then increased by 2.22% to $4.3 million in 2023, then surged by 66.29% to $7.2 million in 2024, then surged by 57.83% to $11.4 million in 2025, then soared by 37.18% to $15.6 million in 2026.
• The last three Share-based Compensation figures came in at $15.6 million (Q1 2026), $11.4 million (Q4 2025), and $11.7 million (Q3 2025), per Business Quant data.